Get the Stockscreener App
23.56
4.71%
1.06
Zai Lab Limited Adr stock is traded at $23.56, with a volume of 323.89K.
It is up +4.71% in the last 24 hours and down -5.00% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$22.50
Open:
$23.07
24h Volume:
323.89K
Relative Volume:
0.41
Market Cap:
$2.64B
Revenue:
$454.68M
Net Income/Loss:
$-178.68M
P/E Ratio:
-14.54
EPS:
-1.6209
Net Cash Flow:
$-135.66M
1W Performance:
-5.04%
1M Performance:
-5.00%
6M Performance:
+1.33%
1Y Performance:
-19.84%
1-Day Range:
$22.88
$24.00
1-Week Range:
$22.12
$25.92
52-Week Range:
$15.96
$30.18
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
23.56 | 2.64B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
510.35 | 129.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.71 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.17 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.00 | 41.97B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Zai Lab (ZLAB) Slips 3.19% as Shares Pull Back Toward Key SupportAggressive Growth Picks - https://www.siam.in/
Zai Lab (ZLAB) Slips 3.19% as Shares Pull Back Toward Key SupportBreakout Trade - https://www.dars.gov.et/
Zai Lab Limited (9688.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer - marketscreener.com
Zai Lab stock trades without a verified September catalyst - AD HOC NEWS
ZLAB - Finviz
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In T - Benzinga
Zai Lab (NasdaqGM:ZLAB) Stock Forecast & Analyst Predictions - Simply Wall Street
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Zai Lab LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
ZLAB Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Slip 2.76%Earnings Surprise Stocks - dars.gov.et
ZLAB Stock Price, Quote & News - Syfe
Zai Lab LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Former Zai Lab (NASDAQ: ZLAB) executive lines up multi-million ADS sale - Stock Titan
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordEPS Miss Report - dars.gov.et
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordOne-Time Loss Impact - dars.gov.et
Zai Lab (NASDAQ: ZLAB) holder lines up Aug. 19 ADS sale after recent trades - Stock Titan
Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB) - Seeking Alpha
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Yahoo Finance
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock - MarketBeat
William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case? - Sahm
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Zai Lab CFO Chen Yajing Sells 619 ADS Shares via Rule 10b5-1 Trading Plan - Kalkine Media
Zai Lab (NASDAQ:ZLAB) Shares Gap DownWhat's Next? - MarketBeat
Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ - Stock Titan
ZLAB (NASDAQ: ZLAB) filer plans sale of 619 American Depositary Shares - Stock Titan
Zai Lab (ZLAB) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Earnings Turnaround - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Guidance vs Actual - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Basic EPS Analysis - dars.gov.et
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen - Sahm
Zai Lab Q2 Earnings Call Highlights - finance.yahoo.com
Zai Lab Q2 Earnings Call Highlights - sharewise.com
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Form 8K ZAI LAB LIMITED For: 6 August By Investing.com - Investing.com Nigeria
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings - MarketBeat
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M - Stock Titan
Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M - Stock Titan
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - BioSpace
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab’s zoci targets previously treated neuroendocrine cancers - Stock Titan
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zai Lab Limited Adr Stock (ZLAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smiley Joshua L | Former Officer |
Aug 20 '26 |
Proposed Sale |
26.18 |
98,653 |
2,582,511 |
0 |
| Chen Yajing | Officer |
Aug 19 '26 |
Proposed Sale |
27.00 |
260 |
7,020 |
0 |
| Lis William | Director |
Aug 12 '26 |
Proposed Sale |
25.00 |
8,506 |
212,650 |
0 |
| Lis William | Director |
Aug 12 '26 |
Sale |
25.00 |
8,506 |
212,650 |
41,931 |
| Chen Yajing | Chief Financial Officer |
Aug 11 '26 |
Sale |
25.00 |
619 |
15,475 |
35,072 |
| Chen Yajing | Officer |
Aug 11 '26 |
Proposed Sale |
25.00 |
619 |
15,475 |
0 |
| GAYNOR RICHARD | Director |
Jul 01 '26 |
Buy |
19.05 |
1,736 |
33,071 |
80,737 |
| Du Ying | Chairperson & CEO |
Jun 30 '26 |
Sale |
18.53 |
7,026 |
130,220 |
1,203,784 |
| Du Ying | Officer |
Jun 30 '26 |
Proposed Sale |
18.53 |
7,026 |
130,220 |
0 |
| Edmondson Frazor Titus III | Chief Legal Officer |
Jun 26 '26 |
Sale |
17.46 |
4,103 |
71,642 |
30,346 |
0.27%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):